What's being teased in the ads for Mauldin's new Healthy Returns newsletter? Editor Chris Wood says, "It’s not a penny stock or risky startup. FDA approval of its blockbuster new drug is just a few short months away—and this one investment alone could hand you a small fortune in 2020."

New “wealth and wellness” letter from Chris Wood, who has worked on a bunch of investment letters for different publishers, and Dr. Michael Roizen, who is a well-known wellness “guru” and works at the Cleveland Clinic. Aims to provide both stock picks for healthcare-related investments, and health tips for readers.